Sana Biotechnology (SANA) Set to Post Quarterly Earnings on Thursday

Sana Biotechnology (NASDAQ:SANA) will likely be announcing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Sana Biotechnology to announce earnings of ($0.1478) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. On average, analysts expect Sana Biotechnology to post ($0.72) EPS for the current fiscal year and ($0.61) EPS for the next fiscal year.

Sana Biotechnology Stock Down 6.6%

Shares of NASDAQ:SANA opened at $2.40 on Tuesday. The firm has a market cap of $718.47 million, a P/E ratio of -3.16 and a beta of 2.18. Sana Biotechnology has a 12-month low of $2.22 and a 12-month high of $5.49. The business has a fifty day simple moving average of $3.01 and a 200 day simple moving average of $3.40.

Analyst Ratings Changes

A number of research firms have commented on SANA. Bank of America reduced their price target on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 21st. Finally, TD Cowen raised Sana Biotechnology to a “strong-buy” rating in a research note on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.60.

About Sana Biotechnology

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company’s approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions.

Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues.